EZH2 has been involved in the tumor progression mechanisms of a variety of cancer types (32), whereas KDM6A and KDM6B have been identified in numerous malignancies with either oncogenic or tumor suppressor roles (33–37). Here, KDM6B is linked to neoplasm.